Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2024-01-10 Board/Management Inform…
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Appointment of a Senior Management, refer enclosed file for details.
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior management, specifically the appointment of Ms. Radhika Shah as Head of Legal and Company Secretary. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events including management changes. The content includes details about the appointment date, role, and a brief profile of the appointee. There is no financial data, earnings information, or report publication mentioned. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2024-01-10 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-01-08 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, stating that the promoter and persons acting in concert have not made any encumbrance on the equity shares held. This is a regulatory compliance disclosure related to shareholding and encumbrance status, not a financial report, management change, or voting result. It fits the category of Major Shareholding Notification (MRQ) as it pertains to shareholding disclosures under SEBI takeover regulations.
2024-01-08 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges confirming that Sanofi India Limited does not fall under the definition of 'Large Corporate' as per a specific SEBI circular related to fund raising by issuance of debt securities. It includes a compliance confirmation and an annexure with initial disclosure details. The document is short (3622 characters) and primarily serves as a regulatory compliance confirmation rather than a financial report or detailed update. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report publication but a regulatory filing to comply with SEBI requirements. Therefore, it fits best under Regulatory Filings (RNS).
2024-01-08 English
Updates
Regulatory Filings Classification · 100% confidence The document is a formal disclosure submitted to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details an order passed by a tax authority (Office of the Assistant Commissioner, CGST & Central Excise Division VIII, Mumbai East) against the company regarding recovery of GST, interest, and penalty. The document is a regulatory announcement about a legal/tax proceeding and does not contain financial statements, earnings data, or management discussion. It is not an annual or interim report, earnings release, or audit report. It is also not a voting result, capital change, or shareholding notification. The content fits best under Regulatory Filings (RNS) as it is a compliance disclosure about a regulatory/tax order.
2024-01-03 English
Announcement under Regulation 30 (LODR)
Regulatory Filings Classification · 95% confidence The document is a formal disclosure submitted to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details an order passed by a tax authority (Office of the Assistant Commissioner, CGST & Central Excise Division VIII, Mumbai East) against the company regarding recovery of GST amounts, interest, and penalty. The document is a regulatory announcement about a legal/tax matter affecting the company, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but is a compliance disclosure of a regulatory/legal event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.